Advertisement

Prostate Ablation

  • Georgia Tsoumakidou
  • Hervé Lang
  • Afshin Gangi
Chapter
Part of the Techniques in Interventional Radiology book series (TECHRAD)

Abstract

Prostate cancer (PCa) is the most prevalent cancer in men and among the three first leading causes of cancer death in both American and European men. PCa affects elderly men more often than young men and thus is a major health problem in the developed countries where the proportion of elderly men is high.

Keywords

Erectile Dysfunction Ablation Zone Freezing Process Urethral Stricture Focal Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18:581–92.PubMedCrossRefGoogle Scholar
  2. 2.
    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. 2010;60:277–300.PubMedCrossRefGoogle Scholar
  3. 3.
    Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000: the global picture. Eur J Cancer. 2001;37 Suppl 8:S4–66.PubMedCrossRefGoogle Scholar
  4. 4.
    Claus FG, Hricak H, Hattery RR. Pretreatment evaluation of prostate cancer: role of MR imaging and 1H MR Spectroscopy. Radiographics. 2004;24:S167.PubMedCrossRefGoogle Scholar
  5. 5.
    McGregor B, Tulloch AG, Quinlan MF, Lovegrove F. The role of bone scanning in the assessment of prostatic carcinoma. Br J Urol. 1978;50:178–81.PubMedCrossRefGoogle Scholar
  6. 6.
    Beheshti M, Vali R, Langsteger W. 18 F-Fluorocholine PET-CT in the assessment of bone metastases in prostate cancer. Eur J Nucl Med Mol Imaging. 2007;34:1316–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Heidenreich A, Bellmunt J, Bolla M, et al. European Association of Urology guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59:61–71.PubMedCrossRefGoogle Scholar
  8. 8.
    Salembier C, Lavagnini P, Nickers P, GEC ESTRO PROBATE Group, et al. Tumour target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy. Radiother Oncol. 2007;83:3–10.PubMedCrossRefGoogle Scholar
  9. 9.
    Potosky AL, Legler J, Albertsen PC, et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcome Study. J Natl Cancer Inst. 2000;92:1582–92.PubMedCrossRefGoogle Scholar
  10. 10.
    Ataman F, Zurlo A, Artignan X, et al. Late toxicity following conventional radiotherapy for prostate cancer: analysis of the EORTC trial 22863. Eur J Cancer. 2004;40:1674–81.PubMedCrossRefGoogle Scholar
  11. 11.
    Onik G, Narayan P, Vaughan D, Dineen M, Brunelle R. Focal “nerve-sparing” cryosurgery for treatment of primary prostate cancer: a new approach to preserving potency. Urology. 2002;60:109–14.PubMedCrossRefGoogle Scholar
  12. 12.
    Onik G. Percutaneous image-guided prostate cancer treatment: cryoablation as a successful example. Tech Vasc Interv Radiol. 2007;10:149–58.PubMedCrossRefGoogle Scholar
  13. 13.
    Ahmed HU, Moore C, Emberton M. Minimally-invasive technologies in uro-oncology: the role of cryotherapy, HIFU and photodynamic therapy in whole gland and focal therapy of localised prostate cancer. Surg Oncol. 2009;18:219–32.PubMedCrossRefGoogle Scholar
  14. 14.
    Theodorescu D. Cancer cryotherapy: evolution and biology. Rev Urol. 2004;6 Suppl 4:S9–19.PubMedGoogle Scholar
  15. 15.
    Mazur P. Cryobiology: the freezing of biological systems. Science. 1970;68:939–49.CrossRefGoogle Scholar
  16. 16.
    Mazur P. The role of intracellular freezing in the death of cells cooled at supraoptimal rates. Cryobiology. 1977;14:251–72.PubMedCrossRefGoogle Scholar
  17. 17.
    Tatsutani K, Rubinsky B, Onik G, Dahiya R. Effect of thermal variables on frozen human primary prostatic adenocarcinoma cells. Urology. 1996;48:441–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Onik G. Image-guided prostate cryosurgery: state of the art. Cancer Control. 2001;8:522–31.PubMedGoogle Scholar
  19. 19.
    Onik GM, Cohen JK, Reyes GD, Rubinsky B, Chang Z, Baust J. Transrectal ultrasound-guided percutaneous radical cryosurgical ablation of the prostate. Cancer. 1993;72:1291–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Saliken JC, Donnelly BJ, Rewcastle JC. The evolution and state of modern techniology for prostate cryosurgery. Urology. 2002;60(Suppl 2A):26–33.PubMedCrossRefGoogle Scholar
  21. 21.
    Cohen JK, Miller RJ, Shuman BA. Urethral warming catheter for use during cryoablation of the prostate. Urology. 1995;45:861–4.PubMedCrossRefGoogle Scholar
  22. 22.
    Long JP, Bahn D, Lee F, Shinohara K, Chinn DO, Macaluso Jr JN. Five-year retrospective, multi-institutional pooled analysis of cancer-related outcomes after cryosurgical ablation of the prostate. Urology. 2001;57:518–23.PubMedCrossRefGoogle Scholar
  23. 23.
    Han KR, Cohen JK, Miller RJ, et al. Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience. J Urol. 2003;170:1126–30.PubMedCrossRefGoogle Scholar
  24. 24.
    Koppie TM, Shinohara K, Grossfeld GD, Presti Jr JC, Carroll PR. The efficacy of cryosurgical ablation of prostate cancer: the University of California, San Francisco experience. J Urol. 1999;162:427–32.PubMedCrossRefGoogle Scholar
  25. 25.
    De La Taille A, Benson MC, Bagiella E, et al. Cryoablation for clinically localized prostate cancer using an argon-based system: complication rates and biochemical recurrence. BJU Int. 2000;85:281–6.CrossRefGoogle Scholar
  26. 26.
    Donelly BJ, Saliken JC, Ernst DS, et al. Prospective trial of cryosurgical ablation of the prostate: five-year results. Urology. 2002;60:645–9.CrossRefGoogle Scholar
  27. 27.
    Bahn DK, Lee F, Badalament R, Kumar A, Greski J, Chernick M. Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology. 2002;60:3–11.PubMedCrossRefGoogle Scholar
  28. 28.
    Rouviere O, Souchon R, Salomir R, Gelet A, Chapelon J-Y, Luonnet D. Tranrectal high-intensity focused ultrasound ablation of prostate cancer: effective treatment requiring accurate imaging. Eur J Radiol. 2007;63:317–27.PubMedCrossRefGoogle Scholar
  29. 29.
    Zhoux YF. High-intensity focused ultrasound in clinical tumor ablation. World J Clin Oncol. 2011;2:8–27.CrossRefGoogle Scholar
  30. 30.
    Gelet A, Chapelon JY, Bouvier R, et al. Transrectal high-intensity focused ultrasound: minimally invasive therapy of localised prostate cancer. J Endourol. 2000;14:519–28.PubMedCrossRefGoogle Scholar
  31. 31.
    Chaussy C, Thuroff S. High-intensity focused ultrasound in prostate cancer: results after 3 years. Mol Urol. 2000;4:179–82.PubMedGoogle Scholar
  32. 32.
    Weersink RA, Forbes J, Bisland S, et al. Assessment of cutaneous photosensitivity of TOOKAD (WST09) in preclinical animal models and patients. Photochem Photobiol. 2005;81:106–13.PubMedCrossRefGoogle Scholar
  33. 33.
    Trachtenberg J, Weersink RA, Davidson SR, et al. Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses. BJU Int. 2008;102:556–62.PubMedCrossRefGoogle Scholar
  34. 34.
    Trachtenberg J, Bogaards A, Weersink RA, et al. Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy; assessment of safety and treatment response. J Urol. 2007;178:1974–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Haider MA, Davidson SR, Kale AV, et al. Prostate gland: MR imaging apperance after vascular targeted photodynamic therapy with palladium-bacteriopheophorbide. Radiology. 2007;244:196–204.PubMedCrossRefGoogle Scholar
  36. 36.
    Woodrum DA, Mynderse LA, Gorny KR, Amrami KK, McNichols RJ, Callstrom MR. 3.0 T MR-guided laser ablation of a prostate cancer recurrence in the postsurgical prostate bed. J Vasc Interv Radiol. 2011;22:929–34.PubMedCrossRefGoogle Scholar
  37. 37.
    Linder U, Lawrentschuk N, Trachtenberg J. Focal laser ablation for localized prostate cancer. J Endourol. 2010;24:791–7.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  • Georgia Tsoumakidou
    • 1
    • 2
    • 3
  • Hervé Lang
    • 3
  • Afshin Gangi
    • 1
    • 2
  1. 1.Department of Interventional RadiologyUniversity Hospital of StrasbourgStrasbourgFrance
  2. 2.Department of Non-vascular Interventional RadiologyUniversity Hospital of StrasbourgStrasbourgFrance
  3. 3.Department of UrologyUniversity Hospital of StrasbourgStrasbourgFrance

Personalised recommendations